secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001171843-25-007795
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose presents tuspetinib triplet therapy data at ASH: 100% CR/CRh at higher doses in AML
--------------------------------------------------------------------------------

- 90% CR/CRh across all doses (40/80/120 mg TUS); 100% at 80 mg and 120 mg levels.
- 78% of responders achieved MRD negativity by central flow cytometry.
- No dose-limiting toxicities or drug-related deaths; febrile neutropenia in 2 subjects (16.7%).
- Responses seen in FLT3-WT, TP53/complex karyotype, RAS, and MDS-related mutations.
- Preliminary data at 160 mg cohort show early blast clearance and MRD negativity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325007795/0001171843-25-007795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325007795/f8k_120525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer